Joseph Leveque has joined San Diego biotech Synthorx as chief medical officer.

Previously Leveque was the chief medical officer of Armo BioSciences, a late-stage company acquired in May by Eli Lilly.

Prior to this, he was chief medical officer of EMD Serono, the North American subsidiary of Merck KGaA and the vice president and head of U.S. medical oncology at Bristol-Myers Squibb, where he was involved in the development and commercialization of immuno-oncology therapeutics.

In April, Synthorx raised $63 million in a series C round. The funding is being directed toward Synthorx’s pipeline of synthorin cytokines, which activate tumor-fighting immune cells.